proteome profiler mouse xl cytokine array kit (R&D Systems)
Structured Review

Proteome Profiler Mouse Xl Cytokine Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 519 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+xl+cytokine/Proteome+Profiler+Mouse+XL+Cytokine+Array/bio_rxiv__64898__2026__04__14__718596-115-7-14
Average 96 stars, based on 519 article reviews
Images
1) Product Images from "NETosis and Myeloperoxidase Promotes Inflammation and Cardiac Remodeling in Arrhythmogenic Cardiomyopathy"
Article Title: NETosis and Myeloperoxidase Promotes Inflammation and Cardiac Remodeling in Arrhythmogenic Cardiomyopathy
Journal: bioRxiv
doi: 10.64898/2026.04.14.718596
Figure Legend Snippet: (A) Representative Western blots clearly show the upregulation of PAD4 and H3Cit in 4-week-old Dsg2 mut/mut cardiac lysates. (B) Quantification of western blots from . Data presented as mean±SEM; n=4 mice/parameter; ***P<0.001 and ****P<0.0001 via two-tailed T-test. (C) Representative ECG tracings from WT, Dsg2 mut/mut , and Dsg2 mut/mut ; Pad4 -/- at 16-weeks of age, respectively. (D) Percent ectopic beats at 16-weeks of age. Data presented as mean±SEM; n≥7. Statistical significance was determined via one-way ANOVA with Tukey’s multiple comparison test (**P<0.01 and ***P<0.001). (E) Percent left ventricular ejection fraction at 16-weeks of age. (F) Percent left ventricular fractional shortening at 16-weeks of age. (G) Stroke Volume at 16-weeks of age. (H) Representative Masson’s trichrome-immunostained hearts from Dsg2 mut/mut and Dsg2 mut/mut ; Pad4 -/- at 16-weeks of age. (I) Percent fibrosis at 16-weeks of age. Data presented as mean±SEM; n≥12. Statistical significance was determined via one-way ANOVA with Tukey’s multiple comparison test for E-G and via two-tailed T-test for I (*P<0.05, ***P<0.001, and ****P<0.0001). (J) Representative cytokine arrays with legend for key cytokines from WT, Dsg2 mut/mut , and Dsg2 mut/mut ; Pad4 -/- mice. (K) Legend of selected cytokines. (L-N) Quantification of selected cytokines normalized to reference band in WT, Dsg2 mut/mut , and Dsg2 mut/mut ; Pad4 -/- mice. Data presented as mean±SEM; n=4. *P<0.05, via two-tailed T-test. C5/C5a, Complement Component C5/C5a; MCP-1, Monocyte Chemoattractant Protein-1; MIP-α/β, Macrophage Inflammatory Protein-1 alpha/beta; MMP-3, Matrix metalloproteinase-3; MMP-9, Matrix metalloproteinase-9; MPO, Myeloperoxidase; NGAL, Neutrophil gelatinase-associated lipocalin; TNFα, Tumor Necrosis Factor-alpha; and OPN, Osteopontin.
Techniques Used: Western Blot, Two Tailed Test, Comparison
Figure Legend Snippet: (A) Schematic timeline of PF1355 treatment and in vivo mouse measurements. (B) Percent left ventricular ejection fraction (%LVEF) at 16-weeks of age. (C) Percent left ventricular fractional shortening (%FS) at 16-weeks of age. Data presented as mean±SEM; n≥5. Statistical significance was determined via two-way ANOVA with Tukey’s multiple comparison test (*P<0.05 and **P<0.01). (D) Representative ECG tracings from PF1355 treated Dsg2 mut/mut , Placebo treated Dsg2 mut/mut , and WT at 16-weeks of age, respectively. Asterisks, ectopic beats. (E) Percent ectopic beats (% Ectopics), (F) R-amplitude, and (G) Q-amplitude at 16-weeks of age. (H) Representative Masson’s trichrome-immunostained hearts from Placebo-treated and PF1355-treated Dsg2 mut/mut at 16-weeks of age. (I) Percent fibrosis at 16-weeks of age. Data presented as mean±SEM; n≥6. Statistical significance was determined via Welch’s t-test for E and one-way ANOVA with Tukey’s multiple comparison test for F,G, and I (*P<0.05). (J) Representative cytokine arrays with legend for key cytokines from Placebo-treated and PF1355-treated Dsg2 mut/mut , and WT mice. (K) Legend of selected cytokines. (L-N) Quantification of selected cytokines normalized to reference band in PF1355-treated and Placebo-treated Dsg2 mut/mut , and WT mice. Data presented as mean±SEM; n=4. *P<0.05, via two-tailed T-test. C5/C5a, Complement Component C5/C5a; CCL11, C-C motif chemokine ligand 11; CCL12, C-C motif chemokine ligand 12; LIX, Lipopolysaccharide-induced CXC chemokine; MCP-1, Monocyte Chemoattractant Protein-1; MIP-α/β, Macrophage Inflammatory Protein-1 alpha/beta; MMP-3, Matrix metalloproteinase-3; MMP-9, Matrix metalloproteinase-9; and NGAL, Neutrophil gelatinase-associated lipocalin. All data presented as mean±SEM. Statistical significance was determined via two-way ANOVA with Tukey’s multiple comparison test for B-C and via two-tailed T-test for E-G, I, and L-N (*P<0.05).
Techniques Used: In Vivo, Comparison, Two Tailed Test
Related Articles
other:Article Title: The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent Article Snippet: Tumor cytokine and angiogenic profiles were determined using the Mouse XL Cytokine and Article Title: The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent Article Snippet: Proteome Pro ler array Tumor cytokine and angiogenic pro les were determined using the Mouse XL Cytokine and |